01Pelthos Therapeutics reported Q2 2026 earnings per share of -$6.62, missing the consensus estimate of -$2.96 by $3.66 per share, representing a 124% miss relative to expectations.
02Revenue came in at $15.6 million, slightly beating the estimate of $15.4 million.
03The company's earnings have deteriorated sequentially, with Q2 losses of -$6.62 per share significantly worse than Q1's -$3.09 per share.
04The stock trades at $27.33 with a market capitalization of $15.5 million as of the earnings report date.
Earnings Results
Pelthos Therapeutics (NYSE:PTHS) reported quarterly earnings results on August 13, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-6.62, missing the consensus estimate of $-2.96 by $3.66 per share. Revenue came in at $15.6M, beating the estimate of $15.4M.
Company Overview
Pelthos Therapeutics's stock moved following the earnings release. The stock currently trades at $27.33 with a market capitalization of $15.5M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 124% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Pelthos Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.